Market Overview

UPDATE: Bank of America Reduces PO to $19 on WuXi PharmaTech on Mixed Outlook

Related WX
Claritas Launches the First Clinical Exome Test That Gives Healthcare Providers Multiple Options to Obtain Answers for Patients Quickly and Cost-Effectively
Benzinga's Weekend M&A Chatter

Bank of America reiterated its Buy rating on WuXi PharmaTech (NYSE: WX) but reduced its price objective from $19.50 to $19.

Bank of America commented, "WuXi reported 3Q12 results that again beat our/consensus revenue and nonGAAP EPS by 1.7% and 16%/2.4% and 24%. Management narrowed its FY12 guidance to the upper end of the previous guided range, while expecting modest margin pressure in 2013. We raise our FY12 EPS by 3%, but reduce our FY13 rev/EPS by 2%/3%, and our PO accordingly. Trading at 10x 2013E PE with midteen's growth prospect in 2014E, strong balance sheet and healthy cash flow, we believe the margin pressure is more than reflected in the share price."

WuXi PharmaTech closed at $15.19 on Monday.

Latest Ratings for WX

Oct 2015Morgan StanleyDowngradesOverweightEqual-weight
Mar 2015Goldman SachsDowngradesConviction BuyNeutral
Nov 2014JefferiesDowngradesBuyHold

View More Analyst Ratings for WX
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Price Target Intraday Update Analyst Ratings


Related Articles (WX)

View Comments and Join the Discussion!

Get Benzinga's Newsletters